Pediatric Epilepsy Trial in Subjects 1-24 Months

Summary

This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 years and older.

Timeline

Start

2000-05

Primary completion

2003-11

Completion

2003-11

Drugs

Indications